Capricor Therapeutics Inc. (4LN2)
FSX
6.93
+0.88 (+14.55%)
Real-time Data
06:00 AM
Day's Range
6.936.94
52 wk Range
2.5830.10
Financial Statements - 4LN2 - Capricor Therapeutics Inc.
Revenue
0▼ 100.0%
Net Income
-105.04M▼ 159.6%
EBITDA
-106.20M▼ 145.7%
Free Cash Flow
-81.53M▼ 96.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 22.27M | 25.17M | 2.55M | 244.89K | 310.25K |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -108.14M | -42.56M | -24.07M | -29.69M | -20.93M | -13.68M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 6.14M | 2.09M | 1.79M | 677.85K | 915.92K | 32.94K |
| Pre Tax Income | -105.04M | -40.46M | -22.28M | -29.01M | -20.02M | -13.65M |
| Income Tax | 1.60K | - | - | - | - | - |
| Net Income | -105.04M | -40.46M | -22.28M | -29.01M | -20.02M | -13.65M |
| EPS Basic | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 |
| EPS Diluted | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 | -0.88 |
| Basic Shares Outstanding | 46.47M | 35.21M | 28.79M | 25.21M | 23.70M | 15.98M |
| Diluted Shares Outstanding | 46.47M | 35.21M | 28.79M | 25.21M | 23.70M | 15.98M |
| Ebit | -101.99M | -42.56M | -24.07M | -29.69M | -20.93M | -13.68M |
| Ebitda | -106.20M | -43.22M | -24.73M | -29.65M | -21.06M | -13.57M |
| Net Income Continuous Operations | -105.04M | -40.46M | -22.28M | -29.01M | -20.02M | -13.65M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
